A Randomized Multicenter Phase 2 Study Of Dsp-7888 Dosing Emulsion In Combination With Bevacizumab Versus Bevacizumab Alone In Patients With Recurrent Or Progressive Glioblastoma Following Initial Therapy
Brief Description Of Study
The BBI-DSP-7888-201G trial is designed to compare the overall survival (OS) between treatment with DSP-7888 Dosing Emulsion plus bevacizumab (Bev) versus Bev alone in patients with recurrent or progressive glioblastoma multiforme (GBM) following initial therapy. This is a randomized, active-controlled, multicenter, open-label, parallel groups, Phase 2 study. Approximately 200 patients will be enrolled from up to 70 investigational sites in the US, Canada, Japan, Taiwan, and South Korea.
Additional Information About The Study
For more details please visit iConnect and/or email us at NCRD-BTC@uphs.upenn.edu